These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 22177454)

  • 1. Lack of somatic mutations in the catalytic domains of CREBBP and EP300 genes implies a role for histone deacetylase inhibition in myeloproliferative neoplasms.
    Andersen CL; Hasselbalch H; Grønbæk K
    Leuk Res; 2012 Apr; 36(4):485-7. PubMed ID: 22177454
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mocetinostat for patients with previously treated, locally advanced/metastatic urothelial carcinoma and inactivating alterations of acetyltransferase genes.
    Grivas P; Mortazavi A; Picus J; Hahn NM; Milowsky MI; Hart LL; Alva A; Bellmunt J; Pal SK; Bambury RM; O'Donnell PH; Gupta S; Guancial EA; Sonpavde GP; Faltaos D; Potvin D; Christensen JG; Chao RC; Rosenberg JE
    Cancer; 2019 Feb; 125(4):533-540. PubMed ID: 30570744
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histone acetylation deficits in lymphoblastoid cell lines from patients with Rubinstein-Taybi syndrome.
    Lopez-Atalaya JP; Gervasini C; Mottadelli F; Spena S; Piccione M; Scarano G; Selicorni A; Barco A; Larizza L
    J Med Genet; 2012 Jan; 49(1):66-74. PubMed ID: 21984751
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular characterization of the histone acetyltransferase CREBBP/EP300 genes in myeloid neoplasia.
    Kongkiatkamon S; Pagliuca S; Adema V; Nagata Y; Kerr CM; Walter W; Awada H; Hutter S; Gurnari C; Rogers HJ; Meggendorfer M; Saunthararajah Y; Haferlach T; Visconte V; Maciejewski JP
    Leukemia; 2022 Apr; 36(4):1185-1188. PubMed ID: 34845315
    [No Abstract]   [Full Text] [Related]  

  • 5. CARM1 inhibition reduces histone acetyltransferase activity causing synthetic lethality in CREBBP/EP300-mutated lymphomas.
    Veazey KJ; Cheng D; Lin K; Villarreal OD; Gao G; Perez-Oquendo M; Van HT; Stratton SA; Green M; Xu H; Lu Y; Bedford MT; Santos MA
    Leukemia; 2020 Dec; 34(12):3269-3285. PubMed ID: 32576962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Whole-transcriptome sequencing identifies a distinct subtype of acute lymphoblastic leukemia with predominant genomic abnormalities of EP300 and CREBBP.
    Qian M; Zhang H; Kham SK; Liu S; Jiang C; Zhao X; Lu Y; Goodings C; Lin TN; Zhang R; Moriyama T; Yin Z; Li Z; Quah TC; Ariffin H; Tan AM; Shen S; Bhojwani D; Hu S; Chen S; Zheng H; Pui CH; Yeoh AE; Yang JJ
    Genome Res; 2017 Feb; 27(2):185-195. PubMed ID: 27903646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inactivating mutations of acetyltransferase genes in B-cell lymphoma.
    Pasqualucci L; Dominguez-Sola D; Chiarenza A; Fabbri G; Grunn A; Trifonov V; Kasper LH; Lerach S; Tang H; Ma J; Rossi D; Chadburn A; Murty VV; Mullighan CG; Gaidano G; Rabadan R; Brindle PK; Dalla-Favera R
    Nature; 2011 Mar; 471(7337):189-95. PubMed ID: 21390126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CREBBP/EP300 mutations promoted tumor progression in diffuse large B-cell lymphoma through altering tumor-associated macrophage polarization via FBXW7-NOTCH-CCL2/CSF1 axis.
    Huang YH; Cai K; Xu PP; Wang L; Huang CX; Fang Y; Cheng S; Sun XJ; Liu F; Huang JY; Ji MM; Zhao WL
    Signal Transduct Target Ther; 2021 Jan; 6(1):10. PubMed ID: 33431788
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Screening of a large Rubinstein-Taybi cohort identified many novel variants and emphasizes the importance of the CREBBP histone acetyltransferase domain.
    Cross E; Duncan-Flavell PJ; Howarth RJ; Hobbs JI; Thomas NS; Bunyan DJ
    Am J Med Genet A; 2020 Nov; 182(11):2508-2520. PubMed ID: 32827181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of histone acetyltransferase function radiosensitizes CREBBP/EP300 mutants via repression of homologous recombination, potentially targeting a gain of function.
    Kumar M; Molkentine D; Molkentine J; Bridges K; Xie T; Yang L; Hefner A; Gao M; Bahri R; Dhawan A; Frederick MJ; Seth S; Abdelhakiem M; Beadle BM; Johnson F; Wang J; Shen L; Heffernan T; Sheth A; Ferris RL; Myers JN; Pickering CR; Skinner HD
    Nat Commun; 2021 Nov; 12(1):6340. PubMed ID: 34732714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inactivation of CREBBP expands the germinal center B cell compartment, down-regulates MHCII expression and promotes DLBCL growth.
    Hashwah H; Schmid CA; Kasser S; Bertram K; Stelling A; Manz MG; Müller A
    Proc Natl Acad Sci U S A; 2017 Sep; 114(36):9701-9706. PubMed ID: 28831000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Confirmation of EP300 gene mutations as a rare cause of Rubinstein-Taybi syndrome.
    Zimmermann N; Acosta AM; Kohlhase J; Bartsch O
    Eur J Hum Genet; 2007 Aug; 15(8):837-42. PubMed ID: 17299436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unique and Shared Epigenetic Programs of the CREBBP and EP300 Acetyltransferases in Germinal Center B Cells Reveal Targetable Dependencies in Lymphoma.
    Meyer SN; Scuoppo C; Vlasevska S; Bal E; Holmes AB; Holloman M; Garcia-Ibanez L; Nataraj S; Duval R; Vantrimpont T; Basso K; Brooks N; Dalla-Favera R; Pasqualucci L
    Immunity; 2019 Sep; 51(3):535-547.e9. PubMed ID: 31519498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. From Whole Gene Deletion to Point Mutations of EP300-Positive Rubinstein-Taybi Patients: New Insights into the Mutational Spectrum and Peculiar Clinical Hallmarks.
    Negri G; Magini P; Milani D; Colapietro P; Rusconi D; Scarano E; Bonati MT; Priolo M; Crippa M; Mazzanti L; Wischmeijer A; Tamburrino F; Pippucci T; Finelli P; Larizza L; Gervasini C
    Hum Mutat; 2016 Feb; 37(2):175-83. PubMed ID: 26486927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rubinstein-Taybi syndrome: clinical and molecular overview.
    Roelfsema JH; Peters DJ
    Expert Rev Mol Med; 2007 Aug; 9(23):1-16. PubMed ID: 17942008
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genome-wide CRISPR screens reveal synthetic lethal interaction between CREBBP and EP300 in diffuse large B-cell lymphoma.
    Nie M; Du L; Ren W; Joung J; Ye X; Shi X; Ciftci S; Liu D; Wu K; Zhang F; Pan-Hammarström Q
    Cell Death Dis; 2021 Apr; 12(5):419. PubMed ID: 33911074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A boy with classical Rubinstein-Taybi syndrome but no detectable mutation in the CREBBP and EP300 genes.
    Caglayan AO; Lechno S; Gumus H; Bartsch O; Fryns JP
    Genet Couns; 2011; 22(4):341-6. PubMed ID: 22303793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Somatic mutations of the CREBBP and EP300 genes affect response to histone deacetylase inhibition in malignant DLBCL clones.
    Andersen CL; Asmar F; Klausen T; Hasselbalch H; Grønbæk K
    Leuk Res Rep; 2012; 2(1):1-3. PubMed ID: 24371765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Somatic EP300-G211S mutations are associated with overall somatic mutational patterns and breast cancer specific survival in triple-negative breast cancer.
    Bemanian V; Noone JC; Sauer T; Touma J; Vetvik K; Søderberg-Naucler C; Lindstrøm JC; Bukholm IR; Kristensen VN; Geisler J
    Breast Cancer Res Treat; 2018 Nov; 172(2):339-351. PubMed ID: 30132219
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploitation of EP300 and CREBBP Lysine Acetyltransferases by Cancer.
    Attar N; Kurdistani SK
    Cold Spring Harb Perspect Med; 2017 Mar; 7(3):. PubMed ID: 27881443
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.